Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMEPDF 81 EV-to-EBITDA is 4.09 as of Aug. 09, 2026, which is 19% below its 10-year median of 5.08. GuruFocus rates MEPDF with a GF Score™ of 81/100 and a GF Value™ of $17.73 (Fairly Valued). The stock has 3 warning signs investors should review. Among 99 Medical Distribution companies, Medipal Holdings ranks better than 81.82% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medipal Holdings's enterprise value is $2,678 Mil.
Medipal Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $655 Mil. Therefore, Medipal Holdings's EV-to-EBITDA for today is 4.09.
The historical rank and industry rank for Medipal Holdings's EV-to-EBITDA or its related term are showing as below:
MEPDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.41 Med: 5.08 Max: 7.4
Current: 4.37
During the past 13 years, the highest EV-to-EBITDA of Medipal Holdings was 7.40. The lowest was 3.41. And the median was 5.08.
MEPDF's EV-to-EBITDA is ranked better than 81.82% of 99
companies
in the Medical Distribution industry
Industry Median: 8.52
vs MEPDF: 4.37
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medipal Holdings's PE Ratio (TTM) for today is calculated as:
Medipal Holdings's share price for today is $18.35.
Medipal Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.368.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medipal Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medipal Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's EV-to-EBITDA falls into.
Medipal Holdings's current Enterprise Value is $2,678 Mil.
Medipal Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $655 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medipal Holdings (MEPDF) has a EV-to-EBITDA of 4.09 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medipal Holdings. This is 19% below median its historical median of 5.08. Over the past decade, Medipal Holdings' EV-to-EBITDA has ranged from 3.41 to 7.40. According to the industry distribution chart, Medipal Holdings ranks #18 out of 99 companies in the Medical Distribution industry, placing it in the top 18.2%.
Is Medipal Holdings' EV-to-EBITDA too high?
Medipal Holdings' current EV-to-EBITDA of 4.09 is 19% below median its 10-year median of 5.08. Over the past 10 years, this metric has ranged from a low of 3.41 to a high of 7.40. The Medical Distribution industry median EV-to-EBITDA is 8.52. Medipal Holdings' value of 4.09 is 52% below this industry median. Based on the distribution chart, Medipal Holdings ranks #18 out of 99 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Medipal Holdings has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #18 out of 99 companies for EV-to-EBITDA. This places Medipal Holdings in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 8.52. Medipal Holdings' value of 4.09 is 52% below this benchmark. Historically, Medipal Holdings' own EV-to-EBITDA has ranged from 3.41 to 7.40 over the past decade. While the company's 10-year median is 5.08 vs. the industry median of 8.52, Medipal Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.52, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current EV-to-EBITDA of 4.09 is 52% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medipal Holdings. For the Medical Distribution industry, the median EV-to-EBITDA is 8.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current EV-to-EBITDA is 4.09, which is 19% below median its own 10-year median of 5.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MEPDF) is currently considered Fairly Valued. The stock's GF Value™ is $17.73, compared to a current price of $18.35 — trading 3.5% above its estimated fair value. The current EV-to-EBITDA is 4.09, which is 19% below median its 10-year median of 5.08 and 52% below the Medical Distribution industry median of 8.52. Medipal Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current EV-to-EBITDA is 4.09 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MEPDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $18.35 is trading 3.5% above its estimated GF Value™ of $17.73.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MEPDF:
EV-to-EBITDA: 4.09 (19% below median its 10-year median of 5.08)
GF Value™: $17.73 vs. price of $18.35 (3.5% above fair value)
Industry Position: 52% below the Medical Distribution median (#18 of 99)
No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score
Get the complete analysis for MEPDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEPDF has been successfully added to your 
